C-ABL-IN-4
C-ABL-IN-4 is a potent inhibitor of c-Abl. Activation of c-Abl has been implicated in various diseases, notably cancer. c-ABL-IN-4 has the potential for the research of neurodegenerative diseases (amyotrophic lateral sclerosis (ALS) and Parkinson’s disease (PD) and cancer (extracted from patent WO2021048567A1, compound 54) [1].
Product Specifications
CAS Number
2626934-68-5
UNSPSC
12352005
Target
Bcr-Abl
Type
Reference compound
Related Pathways
Protein Tyrosine Kinase/RTK
Applications
Cancer-programmed cell death
Field of Research
Cancer; Neurological Disease
Assay Protocol
https://www.medchemexpress.com/c-abl-in-4.html
Solubility
10 mM in DMSO
Smiles
O=C(C1=CN(C(C=C1)=O)C2=CN=CC(F)=C2)NC3=CC=C(C=C3)OC(F)(Cl)F
Molecular Formula
C18H11ClF3N3O3
Molecular Weight
409.75
References & Citations
[1] Michael J. RAWLING, et al. New compounds and methods. Patent WO2021048567A1.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
Recombinant Human Dual specificity protein kinase CLK2 (CLK2), partial
Recombinant Human Dual specificity protein kinase CLK2 (CLK2), partial
Recombinant Human Dual specificity protein kinase CLK2 (CLK2), partial